Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Rendo

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Blood Advances|January 24, 2024
A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trialManuel Carcao, Michele Schiavulli, Roshni Kulkarni, et al.
Medicina|April 23, 2002
[Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer]José M Lastiri, Sergio R Specterman, Pablo Rendo, et al.
Vertex (Buenos Aires, Argentina)|March 3, 2020
[Sublicinal depression: an overlooked problem]Romina Capellino, Gilda Garibotti, Daniela Zacharías, et al.
Thrombosis and Haemostasis|March 24, 2017
Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia BBaolai Hua, Runhui Wu, FeiFei Sun, et al.
Medicine|May 25, 2021
First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in ChinaRenchi Yang, Runhui Wu, Jing Sun, et al.
Thrombosis and Haemostasis|August 22, 2015
Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settingsRafael Parra Lopez, Laszlo Nemes, Victor Jimenez-Yuste, et al.
Journal of Blood Medicine|December 3, 2020
Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label StudiesRenchi Yang, Yongqiang Zhao, Xuefeng Wang, et al.
Scientific Reports|October 16, 2024
Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell diseaseSamuel Lessard, Pauline Rimmelé, Hui Ling, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Blood Advances|January 24, 2024
A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trialManuel Carcao, Michele Schiavulli, Roshni Kulkarni, et al.
Medicina|April 23, 2002
[Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer]José M Lastiri, Sergio R Specterman, Pablo Rendo, et al.
Vertex (Buenos Aires, Argentina)|March 3, 2020
[Sublicinal depression: an overlooked problem]Romina Capellino, Gilda Garibotti, Daniela Zacharías, et al.
Thrombosis and Haemostasis|March 24, 2017
Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia BBaolai Hua, Runhui Wu, FeiFei Sun, et al.
Medicine|May 25, 2021
First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in ChinaRenchi Yang, Runhui Wu, Jing Sun, et al.
Thrombosis and Haemostasis|August 22, 2015
Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settingsRafael Parra Lopez, Laszlo Nemes, Victor Jimenez-Yuste, et al.
Journal of Blood Medicine|December 3, 2020
Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label StudiesRenchi Yang, Yongqiang Zhao, Xuefeng Wang, et al.
Scientific Reports|October 16, 2024
Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell diseaseSamuel Lessard, Pauline Rimmelé, Hui Ling, et al.
Pageof 2